Innovation

Process for Synthesis of Silane Dipeptide Analogs

Temple University
posted on 08/05/2011

The present invention relates to the unexpected discovery that a substituted 1,2-oxasilolane may be efficiently converted to the dilithium salt of a substituted 3-hydroxypropylsilanol using lithium metal, which reductively cleaves the Si-O bond in high yields. The substituted 1,2-oxasilolane starting material is easy to prepare and purify and does not present the same handling problems as chlorosilanes, which have been previously utilized in the synthesis of silyl lithium compounds. The dilithium salt of the 3-hydroxypropylsilanol may be reacted with various nucleophiles. The chemistry disclosed herein may be used to synthesize a silanediol-based dipeptide analog in high yield and in fewer synthetic steps than previously reported.

Suggested Uses

• Silane dipeptide analogs are useful as protease inhibitors. These inhibitors have been used for the treatment of various cancers, notably multiple myeloma.


Innovation Details
 

File Number: 689SS 


IP Protection

Patent Number(s): 61/346516

License Online

This innovation currently is not available for online licensing. Please contact Stephen Nappi at Temple University for more information.

Request more info via email request more info
People

Case Manager:

Stephen Nappi Stephen Nappi

Innovations (0)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

8,805 members 16,684 innovations 159 organizations

Browse

David Kolb, CEO and chairman of the board, Emunamedica LLC.

"We found tremendous value and benefit in using the iBridge Network..."  read more...